<DOC>
	<DOCNO>NCT00001289</DOCNO>
	<brief_summary>Gaucher disease lysosomal storage disease result glycocerebroside accumulation macrophage due genetic deficiency enzyme glucocerebrosidase . It may occur adult occur severely infant , cerebroside also accumulate neuron . Patients Gaucher 's disease experience enlargement liver spleen bone destruction . The condition pass generation generation autosomal recessive inheritance . There actually three type Gaucher 's disease . Type I common form . It chronic non-neuronopathic form , mean disease affect nerve cell . The symptoms type I appear age . Type II appear infancy usually result death patient . Type II acute neuronopathic form affect brain stem . It severe form disease . Type III also neuronopathic , however subacute nature . This mean course illness lie somewhere long-term ( chronic ) short-term ( acute ) . The purpose study examine effect enzyme replacement therapy patient Gaucher 's disease , specifically type directly affect nervous system ( neuronopathic ) . Patients Gaucher 's disease type II III select participate study receive enzyme replacement therapy . Patients participate undergo variety test measure level hemoglobin concentration , liver volume , spleen volume . Improvements measure compare laboratory test measure involvement nervous system .</brief_summary>
	<brief_title>Effects Enzyme Replacement Gaucher 's Disease</brief_title>
	<detailed_description>The purpose study examine effect enzyme replacement therapy patient neuronopathic Gaucher 's disease investigate pathogenesis neurological sign symptom . Macrophage-targeted glucocerebrosidase administer intravenous infusion supervision patient 's private physician initial dosage 60 120 IU per kg body weight weekly every week . Patients categorized treatment responder display clinically significant increase hemoglobin concentration reduction hepatic splenic volume . Improvement parameter time correlate measurement metabolic encephalopathy radiologic , electrophysiologic psychometric measurement neurological involvement .</detailed_description>
	<mesh_term>Gaucher Disease</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . All patient neuropathic Gaucher 's disease partial complete horizontal supranuclear gaze palsy genotype associate neurological involvement . 2 . All candidate must serologically nonreactive hepatitis B human immunodeficiency ( AIDS ) virus . HIV positive patient exclude effect latter illness cognitive performance . 3 . Individuals neoplastic disease exclude . 4 . The general health well candidate must sufficient allow modest amount blood drawing , collection appropriate urine spinal fluid specimen performance necessary roentgenographic magnetic resonance ( MR ) image study . In addition , candidate must able return National Institutes Health ( NIH ) regular basis dictate disease severity monitor laboratory parameter . EXCLUSION CRITERIA : 1 . Patient participate clinical study investigational therapeutic agent Gaucher Disease . 2 . Patient and/or patient 's parent ( ) legal guardian ( ) unable understand nature , scope , possible consequence study . 3 . Patient unable comply protocol , e.g. , uncooperative protocol schedule , refusal agree study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 3, 2008</verification_date>
	<keyword>Enzyme Replacement</keyword>
	<keyword>Type 3 Gaucher 's Disease</keyword>
	<keyword>Lysosomal Storage</keyword>
	<keyword>Supranuclear Gaze Palsy</keyword>
	<keyword>Seizures</keyword>
	<keyword>Mental Retardation</keyword>
	<keyword>Gaucher Disease</keyword>
</DOC>